The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Novavax’s protein-based COVID-19 vaccine, Nuvaxovid, wins FDA approval for older adults and people with underlying health risks under …
FDA greenlights two major therapies offering new hope for patients with IgA nephropathy and giant cell arteritis
On 15 April 2025, the European Medicines Regulatory Network rolled out an interactive trial map—empowering patients and professionals …
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
Already a subscriber? Log in